Skip to content

Author

Enrique Mandado Loureiro

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations

Zilebesiran is a first-in-class, subcutaneously administered small interfering RNA therapeutic that selectively silences angiotensinogen messenger RNA, the transcript encoding the common precursor of all angiotensin peptides and produces durable blood pressure lowering that can persist for up to 6 months after a single dose.

Jawaria, A. Noor, Yusra Zarlashat et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.